📊 ELTX Key Takeaways
Is Elicio Therapeutics, Inc. (ELTX) a Good Investment?
Elicio is a pre-revenue biotech with negative stockholders equity (-1.4M), annual operating burn of -11.6M, and estimated runway of ~1.3 years at current cash burn rates. Despite modest YoY loss improvement, the company's balance sheet is technically insolvent with liabilities exceeding assets, creating substantial financial distress risk without successful near-term clinical advancement or capital infusion.
Elicio Therapeutics remains a pre-revenue biotech with substantial operating and free cash flow losses, so the business is not demonstrating self-sustaining profitability or commercial traction. Financial health is weak: equity is minimal, leverage is high, and current cash appears to cover only a limited runway relative to annual cash burn. While losses improved year over year, that improvement is not enough to offset the company’s funding risk and fragile balance sheet.
Elicio Therapeutics, Inc. Key Strengths (ELTX)
- Net loss improving 23.8% YoY, indicating potential path toward profitability milestone
- Adequate short-term liquidity with current ratio of 2.24x and cash position of 14.9M
- Minimal capital expenditure requirements (16K) typical of asset-light biotech model
- Net loss and diluted EPS improved year over year
- Cash of $18.56M provides near-term operating liquidity
- Current and quick ratios of 2.38x indicate adequate short-term balance sheet liquidity
ELTX Stock Risks: Elicio Therapeutics, Inc. Investment Risks
- Negative stockholders equity of -1.4M indicates technical insolvency; liabilities exceed assets by 1.4M
- Zero revenue with no commercialized products; company entirely dependent on clinical/regulatory success
- Annual free cash burn of -11.7M depletes cash runway to ~1.3 years; requires external funding or revenue generation
- Zero revenue indicates no proven commercial business yet
- Free cash flow burn of roughly $36.97M far exceeds cash reserves, implying likely financing pressure
- Debt-to-equity of 6.11x and only $1.64M of equity reflect a highly stressed capital structure
Key Metrics to Watch
- Clinical trial progression and FDA regulatory milestones for lead candidates
- Quarterly cash burn rate and remaining cash runway duration
- Stockholders equity trajectory and path to positive equity position
- Quarterly cash burn relative to cash balance and funding runway
- Any transition from zero revenue to recurring product or collaboration revenue
Elicio Therapeutics, Inc. (ELTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.24x current ratio provides a solid financial cushion.
ELTX Profit Margin, ROE & Profitability Analysis
ELTX vs Healthcare Sector: How Elicio Therapeutics, Inc. Compares
How Elicio Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Elicio Therapeutics, Inc. Stock Overvalued? ELTX Valuation Analysis 2026
Based on fundamental analysis, Elicio Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Elicio Therapeutics, Inc. Balance Sheet: ELTX Debt, Cash & Liquidity
ELTX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Elicio Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-4.25 indicates the company is currently unprofitable.
ELTX Revenue Growth, EPS Growth & YoY Performance
ELTX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2023 | N/A | -$4.5M | $-0.15 |
| Q3 2022 | N/A | -$8.8M | $-0.30 |
| Q2 2022 | $540.0K | -$8.8M | $-0.30 |
| Q1 2022 | $371.0K | -$14.2M | $-0.48 |
| Q3 2021 | N/A | -$15.6M | $-0.53 |
| Q2 2021 | N/A | -$13.2M | $-0.58 |
| Q1 2021 | N/A | -$13.1M | $-0.91 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Elicio Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
ELTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Elicio Therapeutics, Inc. (CIK: 0001601485)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ELTX
What is the AI rating for ELTX?
Elicio Therapeutics, Inc. (ELTX) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 93% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ELTX's key strengths?
Claude: Net loss improving 23.8% YoY, indicating potential path toward profitability milestone. Adequate short-term liquidity with current ratio of 2.24x and cash position of 14.9M. ChatGPT: Net loss and diluted EPS improved year over year. Cash of $18.56M provides near-term operating liquidity.
What are the risks of investing in ELTX?
Claude: Negative stockholders equity of -1.4M indicates technical insolvency; liabilities exceed assets by 1.4M. Zero revenue with no commercialized products; company entirely dependent on clinical/regulatory success. ChatGPT: Zero revenue indicates no proven commercial business yet. Free cash flow burn of roughly $36.97M far exceeds cash reserves, implying likely financing pressure.
What is ELTX's revenue and growth?
Elicio Therapeutics, Inc. reported revenue of $0.0.
Does ELTX pay dividends?
Elicio Therapeutics, Inc. does not currently pay dividends.
Where can I find ELTX SEC filings?
Official SEC filings for Elicio Therapeutics, Inc. (CIK: 0001601485) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ELTX's EPS?
Elicio Therapeutics, Inc. has a diluted EPS of $-0.65.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ELTX's fundamental grade?
Based on our AI fundamental analysis in June 2026, Elicio Therapeutics, Inc. has a D grade with 93% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ELTX stock overvalued or undervalued?
Valuation metrics for ELTX: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ELTX's AI grade for 2026?
Our dual AI analysis gives Elicio Therapeutics, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ELTX's free cash flow?
Elicio Therapeutics, Inc.'s operating cash flow is $-11.6M, with capital expenditures of $16.0K.
How does ELTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 2.24 (avg: 2).